Absolute calibration of the Gamma Knife® Perfexion™ and delivered dose verification using EPR/alanine dosimetry.

PURPOSE: Elekta Leksell Gamma Knife(®) (LGK) is a radiotherapy beam machine whose features are not compliant with the international calibration protocols for radiotherapy. In this scope, the Laboratoire National Henri Becquerel and the Pitié-Salpêtrière Hospital decided to conceive a new LKG dose calibration method and to compare it with the currently used one. Furthermore, the accuracy of the dose delivered by the LGK machine was checked using an "end-to-end" test. This study also aims to compare doses delivered by the two latest software versions of the Gammaplan treatment planning system (TPS). METHODS: The dosimetric method chosen is the electron paramagnetic resonance (EPR) of alanine. Dose rate (calibration) verification was done without TPS using a spherical phantom. Absolute calibration was done with factors calculated by Monte Carlo simulation (MCNP-X). For "end-to-end" test, irradiations in an anthropomorphic head phantom, close to real treatment conditions, are done using the TPS in order to verify the delivered dose. RESULTS: The comparison of the currently used calibration method with the new one revealed a deviation of +0.8% between the dose rates measured by ion chamber and EPR/alanine. For simple fields configuration (less than 16 mm diameter), the "end-to-end" tests showed out average deviations of -1.7% and -0.9% between the measured dose and the calculated dose by Gammaplan v9 and v10, respectively. CONCLUSIONS: This paper shows there is a good agreement between the new calibration method and the currently used one. There is also a good agreement between the calculated and delivered doses especially for Gammaplan v10.

Calibration of helical tomotherapy machine using EPR/alanine dosimetry.

PURPOSE: Current codes of practice for clinical reference dosimetry of high-energy photon beams in conventional radiotherapy recommend using a 10 x 10 cm2 square field, with the detector at a reference depth of 10 cm in water and 100 cm source to surface distance (SSD) (AAPM TG-51) or 100 cm source-to-axis distance (SAD) (IAEA TRS-398). However, the maximum field size of a helical tomotherapy (HT) machine is 40 x 5 cm2 defined at 85 cm SAD. These nonstandard conditions prevent a direct implementation of these protocols. The purpose of this study is twofold: To check the absorbed dose in water and dose rate calibration of a tomotherapy unit as well as the accuracy of the tomotherapy treatment planning system (TPS) calculations for a specific test case. METHOD: Both topics are based on the use of electron paramagnetic resonance (EPR) using alanine as transfer dosimeter between the Laboratoire National Henri Becquerel (LNHB) 60Co-gamma-ray reference beam and the Institut Curie's HT beam. Irradiations performed in the LNHB reference 60Co-gamma-ray beam allowed setting up the calibration method, which was then implemented and tested at the LNHB 6 MV linac x-ray beam, resulting in a deviation of 1.6% (at a 1% standard uncertainty) relative to the reference value determined with the standard IAEA TRS-398 protocol. RESULTS: HT beam dose rate estimation shows a difference of 2% with the value stated by the manufacturer at a 2% standard uncertainty. A 4% deviation between measured dose and the calculation from the tomotherapy TPS was found. The latter was originated by an inadequate representation of the phantom CT-scan values and, consequently, mass densities within the phantom. This difference has been explained by the mass density values given by the CT-scan and used by the TPS which were not the true ones. Once corrected using Monte Carlo N-Particle simulations to validate the accuracy of this process, the difference between corrected TPS calculations and alanine measured dose values was then found to be around 2% (with 2% standard uncertainty on TPS doses and 1.5% standard uncertainty on EPR measurements). CONCLUSION: Beam dose rate estimation results were found to be in good agreement with the reference value given by the manufacturer at 2% standard uncertainty. Moreover, the dose determination method was set up with a deviation around 2% (at a 2% standard uncertainty).